Get the Stockscreener App
10.53
1.17%
-0.125
Telix Pharmaceuticals Ltd Adr stock is traded at $10.53, with a volume of 93,789.
It is down -1.17% in the last 24 hours and down -17.97% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$10.65
Open:
$10.52
24h Volume:
93,789
Relative Volume:
0.28
Market Cap:
$3.58B
Revenue:
$804.63M
Net Income/Loss:
$-7.13M
P/E Ratio:
-498.82
EPS:
-0.0211
Net Cash Flow:
$-73.42M
1W Performance:
-4.41%
1M Performance:
-17.97%
6M Performance:
-1.27%
1Y Performance:
-4.41%
1-Day Range:
$10.43
$10.59
1-Week Range:
$10.61
$11.38
52-Week Range:
$6.28
$13.11
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
10.53 | 3.58B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-03-25 | Initiated | H.C. Wainwright | Buy |
| Jun-05-25 | Initiated | Wedbush | Outperform |
| Nov-15-24 | Initiated | UBS | Buy |
View All
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth - GlobeNewswire Inc.
Kinzey Capital Management Signals Telix ITM Deal Impact - The Globe and Mail
Telix Director David Gill Boosts Nasdaq ADS Stake - The Globe and Mail
Telix Pharmaceuticals Director David Gill Acquires 11,800 ADS on Nasdaq - kalkine.com.au
Telix Pharmaceuticals Applies to Quote 1,645 Shares Issued Under Employee Stock Purchase Plan - kalkine.com.au
Telix announces acquisition of ITM to create a global radiopharmaceutical powerhouse - BiotechDispatch
Telix (TLX) lines up US$1.65B cancer drug merger—and a big revenue jump - Stock Titan
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion - Yahoo! Finance Canada
Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion - finance.yahoo.com
Telix to acquire ITM in deal worth up to $2.35bn - Pharmaceutical Technology
Telix Strikes $1.65 Billion Deal to Acquire Germany's ITM, Building a Radiopharmaceutical Powerhouse - finance.biggo.com
Health Check: Telix strikes monster $3.3 billion merger deal to form radiopharma giant - Stockhead
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse - GlobeNewswire Inc.
Telix Pharmaceuticals to Merge with ITM Isotope Technologies Munich SE, Forming Advanced Radiopharmaceutical Leader - Kalkine Media
Telix Pharmaceuticals Announces Combination with ITM Isotope Technologies Munich SE - Kalkine
Telix Pharmaceuticals Applies to Quote 108,080 Shares Issued Under Employee Share Plans - Kalkine
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD - investing.com
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Canada
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com UK
Two New York conferences will include Telix presentations - Stock Titan
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway - finance.yahoo.com
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com India
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Australia
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Canada
Telix Pharmaceuticals stock jumps on trial completion, FDA path - Investing.com
Up to 75% of prostate biopsies are negative. Telix enrolled 350 patients. - Stock Titan
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - PR Newswire
Earnings call transcript: Telix H1 2026 profit jumps as guidance holds - Investing.com
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline - TradingView
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix Schedules Aug. 20 Webcast for Half-Year Results - Stock Titan
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - Yahoo Finance
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) on Investors' Radar Despite a 30% One-Year Decline? - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
FDA Alignment to Advance ProstACT Global Phase 3 Trial - GlobeNewswire Inc.
Telix clears FDA protocol review for prostate cancer trial expansion - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Telix Pharmaceuticals Ltd Adr Stock (TLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Behrenbruch Christian | MD & Group CEO |
Apr 29 '26 |
Buy |
14.87 |
33,435 |
497,178 |
20,742,935 |
| Behrenbruch Christian | MD & Group CEO |
Apr 28 '26 |
Buy |
14.48 |
34,500 |
499,560 |
20,709,500 |
| Smith Darren Charlton | Group Chief Financial Officer |
Mar 29 '26 |
Option Exercise |
0.00 |
1,111 |
0 |
11,921 |
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):